Popular search terms:
Search Results
82 results found-
CSL Seqirus will supply millions of doses of adjuvanted cell-based vaccine to support Canadians, in the event the World Health Organization (WHO) declares an influenza pandemic.
https://www.cslseqirus.ca/news/canada-and-csl-seqirus-agree-on-new-pandemic-preparedness-contract -
CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role of enhanced influenza vaccines in preventing influenza and reducing the risks of severe disease at the 10th European Scientific Working group on Influenza (ESWI) conference in Valencia.
https://www.cslseqirus.ca/news/essential-protection-for-older-adults -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news/news-archives -
Recent RWE data show cell-based influenza vaccines offer 20% greater protection in the prevention of test-confirmed influenza in pediatric and adult populations relative to standard egg-based influenza vaccines
https://www.cslseqirus.ca/news/data-at-idweek-2025 -
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20252026-fluad-product-monograph-rev04-avril-2025.pdf -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
FLUCELVAX® Trivalent Influenza Vaccine FLUCELVAX® Trivalent Influenza Vaccine QUAD TIV1c4 TIV2c4 QUAD TIV1c4 TIV2c4 N=663 N=330 N=327 N=656 N=340 N=336 Local Adverse Reactions Injection site 45 (<1) 37 (<1) 41 (0) 22 (0) 19 (0) 19 (0) pain Injection site 13 (0) 13 (0) 10 (0) 12 (0) 11 (0) 10 (0) erythema Injection site 12 (0) 10 (<1) 10 (0) 9 (0) 7 (0) 8 (0) induration Injection site 4 (0) 3 (<1) 5 (0) 5 (0) 4 (0) 5 (0) ecchymosis Systemic Adverse Reactions Headache 19 (<1) 19 (<1) 19 (<1) 9 (<1) 9 (<1) 8 (<1) Fatigue 18 (<1) 22 (<1) 16 (2) 9 (<1) 11 (<1) 9 (<1) Myalgia 15 (<1) 15 (<1) 15 (1) 8 (<1) 9 (<1) 8 (<1) Nausea 10 (<1) 7 (<1) 9 (1) 4 (<1) 4 (0) 4 (<1) Arthralgia 8 (<1) 8 (0) 10 (<1) 6 (<1) 5 (<1) 7 (<1) Loss of 8 (<1) 9 (<1) 8 (<1) 4 (<1) 5 (0) 4 (<1) appetite
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2025-2026-flucelvax-tiv-product-monograph-april-17-2025.pdf -
CSL Seqirus has recently opened its new high-tech cell-based influenza vaccine and antivenom manufacturing facility in Melbourne, Australia.
https://www.cslseqirus.ca/news/facility-opens-in-australia -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.ca/